This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Rehabilitation Medicine  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Vladimir Hachinski, MD, FRCPC, DScMed
London, Ontario

Arch Neurol. 1998;55:1583.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

WHERE desperation prevails, any good news is welcome. One of the most heart-wrenching sights in neurology is watching a young person with MS decline relentlessly into helplessness. All contributors agree that the 2 IFNs tested in prospective randomized trials probably reduce the number of exacerbations and definitely decrease the disease burden assessed by MRI. The ultimate significance of these findings has yet to be determined.

The more substantial and controversial issue is whether IFNs slow the progression of MS. Herndon and Jacobs are encouraged by the results. They posit that most long-term disability is due to axonal loss secondary to multifocal inflammatory demyelination, upon which the IFNs seem to act, and conclude that given climbing costs associated with increased disability, IFNs should be used in most patients with MS. They further state that even if IFNs were not cost-effective, they should be administered because they . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of multiple sclerosis across managed care and fee-for-service systems
Vickrey et al.
Neurology 2000;55:1341-1349.
ABSTRACT | FULL TEXT